JP2010505866A - ヒトにおけるケトコナゾールエナンチオマー - Google Patents

ヒトにおけるケトコナゾールエナンチオマー Download PDF

Info

Publication number
JP2010505866A
JP2010505866A JP2009531558A JP2009531558A JP2010505866A JP 2010505866 A JP2010505866 A JP 2010505866A JP 2009531558 A JP2009531558 A JP 2009531558A JP 2009531558 A JP2009531558 A JP 2009531558A JP 2010505866 A JP2010505866 A JP 2010505866A
Authority
JP
Japan
Prior art keywords
patient
ketoconazole
enantiomer
ketoconazole enantiomer
hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009531558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505866A5 (cg-RX-API-DMAC7.html
Inventor
ティモシー・アンドリュー・スチュアート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortendo AB
Original Assignee
Cortendo Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Invest AB filed Critical Cortendo Invest AB
Publication of JP2010505866A publication Critical patent/JP2010505866A/ja
Publication of JP2010505866A5 publication Critical patent/JP2010505866A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009531558A 2006-10-02 2007-10-02 ヒトにおけるケトコナゾールエナンチオマー Pending JP2010505866A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896306P 2006-10-02 2006-10-02
PCT/US2007/080186 WO2008042898A2 (en) 2006-10-02 2007-10-02 Ketoconazole enantiomer in humans

Publications (2)

Publication Number Publication Date
JP2010505866A true JP2010505866A (ja) 2010-02-25
JP2010505866A5 JP2010505866A5 (cg-RX-API-DMAC7.html) 2010-11-25

Family

ID=39269161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531558A Pending JP2010505866A (ja) 2006-10-02 2007-10-02 ヒトにおけるケトコナゾールエナンチオマー

Country Status (12)

Country Link
US (4) US9198906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2076265A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010505866A (cg-RX-API-DMAC7.html)
AU (1) AU2007303219A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719835A2 (cg-RX-API-DMAC7.html)
CA (1) CA2664800A1 (cg-RX-API-DMAC7.html)
IL (1) IL197986A0 (cg-RX-API-DMAC7.html)
NO (1) NO20091593L (cg-RX-API-DMAC7.html)
NZ (1) NZ576569A (cg-RX-API-DMAC7.html)
RU (1) RU2009116632A (cg-RX-API-DMAC7.html)
WO (1) WO2008042898A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902127B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522873A (ja) * 2019-03-04 2022-04-20 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233843A1 (en) * 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions
AU2007204969A1 (en) * 2006-01-10 2007-07-19 Cortendo Invest Ab Methods and compositions for treating prostate cancer
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
US20160244436A1 (en) * 2013-09-25 2016-08-25 Cortendo Ab (Publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome p450 inhibition and their method of use
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040307A (en) * 1992-12-22 2000-03-21 Sepracor Inc. Methods ad compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
WO2006072881A1 (en) * 2005-01-10 2006-07-13 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4503055A (en) 1979-03-26 1985-03-05 Janssen Pharmaceutica, N.V. Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
WO1994014446A1 (en) 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
IL109728A0 (en) 1993-05-28 1994-08-26 Pfizer Res & Dev Indoles
US5869255A (en) * 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
CA2196174C (en) * 1994-08-09 2005-03-01 Per Marin Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5584790A (en) * 1995-09-08 1996-12-17 Beckman Instruments, Inc. Variable inclination centrifugation assembly for rapid separation of blood
JP3092947B2 (ja) 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
AU3441400A (en) 1999-03-29 2000-10-16 Uutech Limited Peptide
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
BR0010651A (pt) 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
ES2307534T3 (es) 1999-09-28 2008-12-01 Bayer Corporation Agonistas de receptores 3 (r3) del peptido activador de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologicos.
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
EP1409512A1 (en) 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
US20040265827A1 (en) 2001-09-21 2004-12-30 Zhimin Zhu Regulation of human steroid 5-alpha reductase
EP1465667A4 (en) * 2001-09-24 2007-06-27 Merck & Co Inc SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
JP2005528325A (ja) 2001-09-26 2005-09-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｃ１７，２０リアーゼ阻害剤としての置換３−ピリジルインドール類およびインダゾール類
EP1471917A1 (en) * 2002-02-07 2004-11-03 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
WO2004052390A1 (en) 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2005113516A1 (en) 2004-05-14 2005-12-01 Neurocrine Biosciences, Inc. Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
AU2007204969A1 (en) * 2006-01-10 2007-07-19 Cortendo Invest Ab Methods and compositions for treating prostate cancer
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040307A (en) * 1992-12-22 2000-03-21 Sepracor Inc. Methods ad compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
WO2006072881A1 (en) * 2005-01-10 2006-07-13 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012021638; ＲＯＴＳＴＥＩＮ，Ｄ．Ｍ． ｅｔ ａｌ: 'Ｓｔｅｒｅｏｉｓｏｍｅｒｓ ｏｆ ｋｅｔｏｃｏｎａｚｏｌｅ： ｐｒｅｐａｒａｔｉｏｎ ａｎｄ ｂｉｏｌｏｇｉｃａｌ ａｃｔｉｖｉｔｙ' Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３５， Ｎｏ．１５, 1992, ｐ．２８１８-２８２５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522873A (ja) * 2019-03-04 2022-04-20 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法
JP7574204B2 (ja) 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法
JP2025026838A (ja) * 2019-03-04 2025-02-26 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法
US12377096B2 (en) 2019-03-04 2025-08-05 Xeris Pharmaceuticals, Inc. Methods of treating disease with levoketoconazole

Also Published As

Publication number Publication date
US20100093755A1 (en) 2010-04-15
US20180125841A1 (en) 2018-05-10
EP2076265A4 (en) 2010-09-22
WO2008042898A9 (en) 2008-09-04
WO2008042898A2 (en) 2008-04-10
BRPI0719835A2 (pt) 2014-05-06
ZA200902127B (en) 2010-07-28
EP2076265A2 (en) 2009-07-08
AU2007303219A1 (en) 2008-04-10
RU2009116632A (ru) 2010-11-10
WO2008042898A3 (en) 2008-10-23
US20190209555A1 (en) 2019-07-11
CA2664800A1 (en) 2008-04-10
NO20091593L (no) 2009-04-22
NZ576569A (en) 2012-05-25
US9198906B2 (en) 2015-12-01
IL197986A0 (en) 2009-12-24
US20160067243A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
US20190209555A1 (en) Ketoconazole enantiomer in humans
Ishibashi et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
JP2025137510A (ja) Ｃｙｐ３ａ４基質薬物による処置方法
Koh et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
JP5358095B2 (ja) 糖尿病、メタボリック症候群、および他の状態を治療するための方法および組成物
US6369103B1 (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
Farnier et al. Lipid‐altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high‐risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy–The IN‐CROSS study
MXPA01007905A (es) Combinaciones de farmacos que comprenden acido (e) -7- (4- (4- fluorofenil) -6- isopropil -2- (metil (metilsulfonil) amino) pirimidin -5- il) (3r, 5s) -3, 5- dihidroxihept -6- enoico y un inhibidor, inductor o substrato de la isoenzima 3a4 de p450.
Koren et al. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial
Hu et al. Current perspectives on rosuvastatin
JP2023181451A (ja) 高トリグリセライド血症の治療方法
Sone et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes
Shua-Haim et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: an open-label, crossover, single-centre study
Wierzbicki et al. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia
Vaidyanathan et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects
Pandian et al. Targeting mulitple dyslipidemias with fixed combinations–focus on extended release niacin and simvastatin
JP2021535136A (ja) 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤
JP2008528603A (ja) ＰＰＡＲ−αモジュレータの製剤及び投与計画
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
Goyal et al. Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials
Martell-Claros et al. Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study
Yamashita et al. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine
Lai et al. Longitudinal association of statin treatment with insulin sensitivity and beta-cell function in the PROMISE cohort
Alajlan et al. The Effects of Itraconazole on the Lipid Profile in Humans and Rabbits
Reddy THE ANTI-HYPERTENSIVE EFFECTS OF HIGH DOSE TELMISARTAN AND LOW DOSE COMBINATION THERAPY TELMISARTAN+ AMLODIPINE IN PATIENTS WITH HYPERTENSION, AT GGH, BY DEPARTMENT OF PHARMACOLOGY, KURNOOL MEDICAL COLLEGE, KURNOOL, ANDHRA PRADESH-A PROSPECTIVE STUDY".

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131112